Contineum Therapeutics, Inc.
SEC CIK 1855175 · CTNM · last insider filing 2026-06-26
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Ignelzi Troy A. | Director | filed 2024 - 2026 |
| Boyce Sarah | Director | filed 2024 - 2026 |
| Ware Olivia C | Director | filed 2024 - 2026 |
| Lyons-Williams Lori | Director | filed 2024 - 2026 |
| Schimmelpennink Evert B. | Director | filed 2024 - 2026 |
| Brady Todd R. | Director | filed 2024 - 2026 |
| Miralles Gines Diego | Director | filed 2025 - 2026 |
| Stengone Carmine N. | Director · CEO and President | filed 2024 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer | filed 2024 - 2026 |
| Watkins Tim | CMO & Head of Development | filed 2025 - 2026 |
| Slover Peter T | Chief Financial Officer | filed 2024 - 2026 |
| Healy John Stephen | General Counsel and Corp Sec | filed 2024 - 2026 |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | filed 2024 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.